Kintara Therapeutics (NASDAQ:KTRA) announced its quarterly earnings results on Friday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.05), MarketWatch Earnings reports.
Shares of KTRA opened at $1.28 on Monday. The business’s 50-day moving average is $1.47 and its two-hundred day moving average is $1.89. The company has a market capitalization of $41.45 million, a P/E ratio of -0.64 and a beta of 1.62. Kintara Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $3.35.
Separately, Aegis increased their price target on Kintara Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, February 3rd.
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.
Recommended Story: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.